<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03752827</url>
  </required_header>
  <id_info>
    <org_study_id>RC-002</org_study_id>
    <nct_id>NCT03752827</nct_id>
  </id_info>
  <brief_title>Autologous Adult Adipose-Derived Regenerative Cell Injection Into Chronic Partial-Thickness Rotator Cuff Tears</brief_title>
  <official_title>A Prospective, Double-Blinded, Multi-Center Pivotal Trial of Autologous Adult Adipose-Derived Regenerative Cell Injection Into Chronic Partial-Thickness Rotator Cuff Tears</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InGeneron, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InGeneron, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to evaluate the safety and superior effectiveness in&#xD;
      functional improvement in patients with partial-thickness rotator cuff tears (PTRCTs) after&#xD;
      the administration of a single injection of adipose-derived regenerative cells (ADRCs) into&#xD;
      the partial-thickness rotator cuff tear compared to the administration of a single&#xD;
      corticosteroid injection into the associated subacromial space.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, double-blinded, randomized, active-controlled, multi-site, pivotal&#xD;
      safety and superior effectiveness study in patients with symptomatic partial-thickness&#xD;
      rotator cuff tears comparing a single ADRC injection generated with the Transpose® RT system&#xD;
      into the supraspinatus tendon and surrounding area to standard-of-care (SOC) corticosteroid&#xD;
      injection into the subacromial bursa.&#xD;
&#xD;
      Up to 20 U.S. centers will be initiated to enroll in the study. 246 subjects assigned to two&#xD;
      randomization arms will be enrolled: an adipose-derived regenerative cell (ADRC) injection&#xD;
      arm (ADRC treatment arm) and the SOC corticosteroid injection arm (active control arm). All&#xD;
      subjects will be randomly assigned to ADRC treatment or active control arms in a 2:1 ratio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>It is a double-blinded trial in which the subject, post-procedural investigator and imaging core laboratory radiologists are blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Pain: VAS</measure>
    <time_frame>24 weeks</time_frame>
    <description>≥ 14-millimeter (mm) improvement in Visual Analog Scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement or no worsening in supraspinatus strength</measure>
    <time_frame>24 weeks</time_frame>
    <description>supraspinatus strength on the MRC Muscle Scale compared to baseline For supraspinatus strength on the MRC Muscle Scale compared to baseline&#xD;
• For subjects with normal supraspinatus strength (MRC Muscle Scale = 5] at baseline: no worsening in supraspinatus strength on the MRC Muscle Scale compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who demonstrate ≥ 14 mm improvement in VAS</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pain score compared to baseline at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who demonstrate improvement or no worsening of supraspinatus strength on the MRC Muscle Scale</measure>
    <time_frame>24 weeks</time_frame>
    <description>Supraspinatus strength on the MRC Muscle Scale compared to baseline at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean improvement in VAS - Pain score</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>VAS pain score compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean improvement in WORC score</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>WORC score compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who demonstrate a ≥ 1-grade improvement in supraspinatus strength on the MRC Muscle Scale</measure>
    <time_frame>24 weeks</time_frame>
    <description>Supraspinatus strength on the MRC Muscle Scale compared to baseline at 24 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean improvement in Rand Short Form-36 score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rand Form-36 score compared at baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of subject satisfaction with treatment on a VAS scale (VAS - Satisfaction)</measure>
    <time_frame>24 weeks</time_frame>
    <description>VAS satisfaction score improvement</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of EuroQoL-5D-5L (EQ-5D-5L)</measure>
    <time_frame>24 weeks</time_frame>
    <description>EuroQoL -5D-5L score</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of Shoulder Activity Level</measure>
    <time_frame>24 weeks</time_frame>
    <description>Recording shoulder activity level</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of shoulder motion (forward elevation, shoulder abduction in the plane of the scapula)</measure>
    <time_frame>24 weeks</time_frame>
    <description>As determined by goniometer</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Rotator Cuff Tear</condition>
  <condition>Rotator Cuff Tendinitis</condition>
  <arm_group>
    <arm_group_label>Adipose Derived Regenerative Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adipose-derived regenerative cell injection into the area of the supraspinatus tendon tear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the active control arm will receive a corticosteroid injection into the subacromial space using ultrasound (US) guidance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adipose Derived Regenerative Cells</intervention_name>
    <description>Adipose-derived regenerative cells isolated with the Transpose Ultra system</description>
    <arm_group_label>Adipose Derived Regenerative Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>Corticosteroid injection into subacrominal space</description>
    <arm_group_label>Corticosteroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females 30-75 years of age (inclusive).&#xD;
&#xD;
          2. Subjects have a minimum of three (3) months of clinical symptoms consistent with a&#xD;
             partial-thickness rotator cuff tear including but not limited to pain, muscle&#xD;
             weakness, or limited active range of motion (AROM).&#xD;
&#xD;
          3. Subjects have &gt; 70% passive range of motion (PROM) of the index shoulder.&#xD;
&#xD;
          4. Subjects have a baseline VAS - Pain score of ≥ 30 mm.&#xD;
&#xD;
          5. Subjects have a partial-thickness rotator cuff tear, defined as ≥25% partial-thickness&#xD;
             tear of the supraspinatus tendon on a 1.5 Tesla (1.5T) or a 3 Tesla (3T) MRI within&#xD;
             the last 3 months, as determined by the Investigator.&#xD;
&#xD;
          6. Subjects can give appropriate consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 30 or &gt; 75.&#xD;
&#xD;
          2. Subject has an insufficient amount of subcutaneous tissue to allow recovery of 100&#xD;
             milliliters (mL) of adipose tissue.&#xD;
&#xD;
          3. Subjects who have received a corticosteroid injection in the index subacromial bursa&#xD;
             within the last 3 months.&#xD;
&#xD;
          4. Subjects who have received more than one (1) previous corticosteroid injections or any&#xD;
             biologic treatment in the index subacromial bursa within the past 6 months.&#xD;
&#xD;
          5. Subjects with severe arthrosis of the glenohumeral or acromioclavicular joint.&#xD;
&#xD;
          6. Subjects with a full-thickness tear of the rotator cuff.&#xD;
&#xD;
          7. Subjects who have undergone major surgery on the affected shoulder meeting one of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Performed as treatment for (or required manipulation of) the rotator cuff.&#xD;
                  Examples include, but are not limited to, subacromial decompression, rotator cuff&#xD;
                  repair, SLAP repair, arthroplasty and fracture fixation with implants that&#xD;
                  involve or penetrate the rotator cuff; OR&#xD;
&#xD;
               -  Performed using implants that interfere with MR visualization and/or evaluation&#xD;
                  of the supraspinatus tendon (e.g., biceps tenodesis); OR&#xD;
&#xD;
               -  Performed in/on the glenohumeral joint, subacromial space, or acromioclavicular&#xD;
                  joint within the last 3 years (e.g. soft tissue Bankart repairs performed &gt;3&#xD;
                  years ago may still qualify).&#xD;
&#xD;
             NOTE: This exclusion criterion does not apply to minor soft tissue procedures with&#xD;
             short recovery periods that do not involve musculoskeletal structures (e.g., lipoma&#xD;
             excision).&#xD;
&#xD;
          8. Subjects who were diagnosed with or treated for adhesive capsulitis of the index&#xD;
             shoulder within the last 5 years.&#xD;
&#xD;
          9. Subjects with current cervical radiculopathy impacting the index shoulder.&#xD;
&#xD;
         10. Subjects who require the use of index arm for ambulation or mobilization via&#xD;
             wheelchair, walker, crutches or cane.&#xD;
&#xD;
         11. Subjects with any contraindication to MRI scan according to MRI guidelines, or who are&#xD;
             unwilling to undergo MRI procedures.&#xD;
&#xD;
         12. Subjects whose pain behavior or pain medication usage is, in the opinion of the&#xD;
             Investigator, out of proportion to the underlying clinical condition or could&#xD;
             interfere with the study- required assessments.&#xD;
&#xD;
         13. Subjects with a history of systemic malignant neoplasms within the last 5 years.&#xD;
&#xD;
         14. Subjects with biopsy-proven, malignant or local neoplasm within the last 6 months or&#xD;
             any history of local neoplasm at the site of administration (on the affected arm),&#xD;
             excluding basal cell carcinoma.&#xD;
&#xD;
         15. Subject is receiving immunosuppressant therapy or has a known immunologic or severe&#xD;
             autoimmune disease that requires chronic systemic immunosuppressive or&#xD;
             immunomodulatory therapy (e.g., human immunodeficiency virus, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, etc.). [Note: Topical or inhaled corticosteroids&#xD;
             are permitted.]&#xD;
&#xD;
         16. Subject is on an active regimen of chemotherapy or radiation- based treatment.&#xD;
&#xD;
         17. Subjects with an allergy to sodium citrate or any &quot;caine&quot; type of local anesthetic.&#xD;
&#xD;
         18. Subject is pregnant or breastfeeding or plans to become pregnant in the next 12&#xD;
             months.&#xD;
&#xD;
         19. Subjects with clinically significant abnormal Lab tests (i.e. basic metabolic panel&#xD;
             (BMP) or equivalent (e.g. CHEM-7), complete blood count (CBC), Liver function tests&#xD;
             (LFTs), and prothrombin time/international normalized ratio (PT/INR)) as interpreted&#xD;
             by the Investigator.&#xD;
&#xD;
        21. Subjects with a history of a bleeding diathesis or coagulopathy&#xD;
&#xD;
        22. Subject is, in the opinion of the Investigator, unable to comply with the requirements&#xD;
        of the study protocol or is unsuitable for the study for any reason. Examples include the&#xD;
        inability of the subject to complete patient-reported outcome instruments (PROs) and the&#xD;
        inability of the Investigator to perform the injection procedure properly because of&#xD;
        anatomic limitations of the subject.&#xD;
&#xD;
        23. Subject is currently participating in another clinical trial that has not yet completed&#xD;
        its primary endpoint. (Noninterventional observational studies are not exclusionary.)&#xD;
&#xD;
        24. Subject 1) is a litigant in a civil suit that could affect the subject's ability to&#xD;
        complete the study related activities or 2) is a defendant in a criminal case or 3) has an&#xD;
        active workman's compensation case in progress.&#xD;
&#xD;
        25. Subject is part of a vulnerable population who, in the judgment of the Investigator, is&#xD;
        unable to give informed consent for reasons of incapacity, immaturity, adverse personal.&#xD;
        circumstances or lack of autonomy. This may include: individuals with a mental disability,&#xD;
        persons in nursing homes, children, impoverished persons, persons in emergency situations,&#xD;
        homeless persons, nomads, refugees, and those incapable of giving informed consent.&#xD;
        Vulnerable populations also may include members of a group with a hierarchical structure&#xD;
        such as university students, subordinate hospital and laboratory personnel, employees of&#xD;
        the Sponsor, members of the armed forces, and persons kept in detention.&#xD;
&#xD;
        26. Uncooperative subjects or those with neurological/psychiatric disorders who are&#xD;
        incapable of following directions or who are predictably unwilling to return for follow-up&#xD;
        examinations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Hurd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanford Orthopedics &amp; Sports Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Caballero</last_name>
    <phone>(713) 440 9900</phone>
    <phone_ext>115</phone_ext>
    <email>bcaballero@ingeneron.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire Huang, PhD</last_name>
    <phone>713 440 9900</phone>
    <phone_ext>102</phone_ext>
    <email>chuang@ingeneron.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan White</last_name>
      <email>mwhite@azresearchcenter.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Gimbel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Biosolutions Clinical Research Center</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Tamara Packard</last_name>
      <email>tamara@biosolutionsresearch.com</email>
    </contact>
    <investigator>
      <last_name>Peter Hanson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sana Ijaz</last_name>
      <email>sijaz@lotuscr.com</email>
    </contact>
    <investigator>
      <last_name>Alina Beaton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sports and Orthopedic Center</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Garcia</last_name>
      <email>agarcia@advancedresearchfl.com</email>
    </contact>
    <investigator>
      <last_name>Manish Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universal Axon Clinical Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Benitez</last_name>
      <email>Abenitez@uaclinical.com</email>
    </contact>
    <investigator>
      <last_name>Luis Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shrock Clinical Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Motes</last_name>
      <email>jennifer@shrockresearch.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Shrock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Andrews Institute for Orthopaedics and Sports Medicine</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecelia Delacey</last_name>
      <email>cecelia.delacey@andrewsref.org</email>
    </contact>
    <investigator>
      <last_name>Joshua Hackel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Institute for Clinical Research</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelita Kitchcart</last_name>
      <email>shelita.kithcart@lowbackpain.com</email>
    </contact>
    <investigator>
      <last_name>Anthony Grasso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blaire Williams</last_name>
      <email>Bwilliams7@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Jaime Garza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanford Medical Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Letourneau</last_name>
      <email>heather.letourneau@SanfordHealth.org</email>
    </contact>
    <contact_backup>
      <email>stemcelltherapy@sanfordhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Lundeen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Orthopedic Clinic/Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Atkins</last_name>
      <email>Kristi.Atkins@SanfordHealth.org</email>
    </contact>
    <contact_backup>
      <email>stemcelltherapy@sanfordhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Hurd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HD Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salma Mustafa</last_name>
      <email>sveramustafa@lotuscr.com</email>
    </contact>
    <investigator>
      <last_name>Daneshvari Solanki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Plastic Surgery</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Krieger</last_name>
      <email>jkrieger@txps.net</email>
    </contact>
    <investigator>
      <last_name>Jaime Garza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2018</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rotator cuff tear</keyword>
  <keyword>adipose-derived regenerative cells</keyword>
  <keyword>adipose-derived stem cells</keyword>
  <keyword>partial rotator cuff tears</keyword>
  <keyword>corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

